Trial of three drugs plus temodar

From Glioblastoma Treatments
Revision as of 05:04, 20 March 2024 by Lazy (talk | contribs) (Created page with "{{TreatmentInfo |drug_name=Combination of Repurposed Drugs plus Temodar |FDA_approval=Varies (individual drugs have separate FDA approvals for other conditions) |used_for=Investigational use in glioblastoma |clinical_trial_phase=Phase 1 and Phase 2 trials |common_side_effects=Varies based on the combination; potential for increased chemotherapy toxicity |OS_without=Standard treatment: median survival of 16.1 months |OS_with=Varies; one combination showed median survival...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search
Property Information
Drug Name Combination of Repurposed Drugs plus Temodar
FDA Approval Varies (individual drugs have separate FDA approvals for other conditions)
Used for Investigational use in glioblastoma
Clinical Trial Phase Phase 1 and Phase 2 trials
Clinical Trial Explanation Not specified
Common Side Effects Varies based on the combination; potential for increased chemotherapy toxicity
OS without Standard treatment: median survival of 16.1 months
OS with Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid
PFS without Not specified
PFS with Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.


From Ben Williams Book: Not specified

Loading comments...